Nachrichten zur Nektar Therapeutics Corp. Aktie

Form 8-K NEKTAR THERAPEUTICS For: Feb 28

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Nektar Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results

SAN FRANCISCO, Feb. 28, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter and…

Form 10-K NEKTAR THERAPEUTICS For: Dec 31

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Nektar sheds 45% as trial setback prompts Jefferies downgrade

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Boeing stock slips after deliveries of 787s halted; Beyond Meat shares rally after plant-food maker’s results

Boeing, Beyond Meat and Nektar Therapeutics are some of the most active stocks in premarket trade....…

Nektar Therapeutics plunges 29% after hours on mid-stage lupus treatment failure

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Stocks to Watch: Beyond Meat, Nektar Therapeutics, ContextLogic, Sweetgreen, SELLAS Life Sciences

Stocks to Watch: Beyond Meat, Nektar Therapeutics, ContextLogic, Sweetgreen, SELLAS Life Sciences...…

Nektar stock drops more than 30% after study involving lupus treatment will not go forward

Shares of Nektar Therapeutics NKTR plunged more than 30% in the extended session Thursday after the biopharma company reported that…

Nektar Therapeutics Phase 2 Rezpegaldesleukin Study Did Not Meet Endpoints

Nektar Therapeutics Phase 2 Rezpegaldesleukin Study Did Not Meet Endpoints...…

Form 8-K NEKTAR THERAPEUTICS For: Feb 23

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Nektar Therapeutics Announces Phase 2 Topline Data for Rezpegaldesleukin in Patients with Systemic Lupus Erythematosus

Improvement in SLEDAI-2K score observed as compared to placebo, although study did not meet primary endpoint Clinically meaningful improvements observed…

Insiderhandel: President & CEO verkauft Aktien von Nektar Therapeutics im Wert von 58.905$

Robin, Howard W. - Vorstand - Tag der Transaktion: 2023-02-16...…

Insiderhandel: Chief Legal Officer verkauft Aktien von Nektar Therapeutics im Wert von 24.825$

Wilson, Mark Andrew - Vorstand - Tag der Transaktion: 2023-02-16...…

Insiderhandel: Chief R&D Officer verkauft Aktien von Nektar Therapeutics im Wert von 31.452$

Zalevsky, Jonathan - Vorstand - Tag der Transaktion: 2023-02-16...…

Insiderhandel: Chief Financial Officer verkauft Aktien von Nektar Therapeutics im Wert von 30.801$

Thomsen, Jillian B. - Vorstand - Tag der Transaktion: 2023-02-16...…

Skye Bioscience Appoints Deborah Charych, PhD to Board of Directors

San Diego, California--(Newsfile Corp. - February 16, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical…

Moore Kuehn, PLLC Encourages Investors of Nektar Therapeutics to Contact Law Firm

NEW YORK, Dec. 15, 2022 /PRNewswire/ -- Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating…

Nektar Announces Poster Presentations at the 64th American Society of Hematology (ASH) Annual Meeting

-- Unveils Trial Design for Nektar Phase 2/3 Study Combining NKTR-255 with CAR-T Therapies -- -- Presents First Data for…

Moore Kuehn, PLLC Encourages Investors of Nektar Therapeutics to Contact Law Firm

New York, New York--(Newsfile Corp. - December 8, 2022) - Moore Kuehn, PLLC, a securities law firm located on…

Insiderhandel: Chief R&D Officer verkauft Aktien von Nektar Therapeutics im Wert von 48.052$

Zalevsky, Jonathan - Vorstand - Tag der Transaktion: 2022-11-16...…

Insiderhandel: Chief Legal Officer verkauft Aktien von Nektar Therapeutics im Wert von 31.023$

Wilson, Mark Andrew - Vorstand - Tag der Transaktion: 2022-11-16...…

Insiderhandel: President & CEO verkauft Aktien von Nektar Therapeutics im Wert von 135.710$

Robin, Howard W. - Vorstand - Tag der Transaktion: 2022-11-16...…

Insiderhandel: Chief Financial Officer verkauft Aktien von Nektar Therapeutics im Wert von 39.609$

Thomsen, Jillian B. - Vorstand - Tag der Transaktion: 2022-11-16...…

Pre-market Movers: Opiant Pharmaceuticals, MorphoSys, Tremor International, The Oncology Institute, Nektar Therapeutics

MARTINSRIED (dpa-AFX) - The following are some of the stocks making big moves in Mondays pre-market trading (as of 06.50…

Nektar Therapeutics Presents Preclinical Data from Novel PEGylated Interferon Gamma Program, NKTR-288, at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

NKTR-288 upregulated MHC Class I and PD-L1 expression on tumors, enhancing anti-tumor activity when combined with anti-PD-1 or anti-PD-L1 antibodies…

Form 10-Q NEKTAR THERAPEUTICS For: Sep 30

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Nektar Therapeutics Q3 Loss decreases, beats estimates

WASHINGTON (dpa-AFX) - Nektar Therapeutics (NKTR) released Loss for third quarter that decreased from the same period last year and…

Nektar Therapeutics Reports Third Quarter 2022 Financial Results

SAN FRANCISCO, Nov. 3, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended…

Form 8-K NEKTAR THERAPEUTICS For: Nov 03

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Nektar to Announce Financial Results for the Third Quarter 2022 on Thursday, November 3, 2022, After Close of U.S.-Based Financial Markets

SAN FRANCISCO, Oct. 25, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter…

dpa-AFX ProFeed